Figure 1.

SVR12 rates. Virologic outcome of patients treated with elbasvir (EBR)/grazoprevir (GZR). SVR12, sustained virologic response (SVR) at 12 weeks after completion of therapy; FAS, full analysis set; mFAS, modified FAS; AE, adverse event. ^* Includes all patients who received at least one dose of study medication; ^† Excludes patients who discontinued treatment for reasons unrelated to study medication; ^‡ One patient withdrew consent and did not achieve SVR12. This patient was excluded from the mFAS analysis.